Institute for Cancer Research
Institute for Cancer Research has since its foundation in 1954 played a central role within the field of cancer research both in Norway and internationally. The Institute has seven research departments and more than 320 employees, master students included. About 70% of the employees and projects are externally funded.
The Institute has internationally strong research groups within biochemistry, cell and tumor biology, genetics, radiation biology, immunology and cancer prevention. For more than 30 years there has been a close interaction between researchers at the Institute and cancer surgeons, oncologists and pathologists. This emphasis on translational science has resulted in numerous clinical protocols based on in-house research, and the Institute is a key partner in the Comprehensive Cancer Center, organizationally under the Division of Surgery and Cancer Treatment at Oslo University Hospital.
Scientific production - Institute for Cancer Research
Kari Kværner, head of the Innovation section at Oslo University Hospital and leader of the "Centre for Connected Care – Accelerating adoption and diffusion of patient-centric innovations" - one 17 new Centres for Research-based Innovation (SFI) appointed by the Research Council of Norway - has recently written an article for the the Oslo University Hospital research blog (in Norwegian). The title of her piece is (translated to) "We must listen end learn in order to deliver what the patients need".
The SFI centre she will be leading starts up August 15th, and has a total budget of 217,6 mill NOK, securing operation for 8 years.
This is a unique seminar with the winners of the Olav Thon Foundation International Research Prize within the fields of medical as well as mathematics and natural sciences for 2015: Judith Campisi (Buck Institute for Research on Aging, USA) and Yossi Shiloh (Tel Aviv University, Israel). Doctor of honour at the University of Oslo, Vilhelm A. Bohr, NIH, will conclude the seminar with his lecture.
The seminar is a collaboration between the Olav Thon Foundation, University of Oslo (UiO) the Healthy Brain Ageing Centre (HBAC) research network and Tone Tønjum's Genome Network group at Oslo University Hospital / UiO.
Time: Thursday, March 5th, 2015 at 12:00 - 15:00
Place: DM4, The Rotunda at University of Oslo (UiO), Gaustad
The research section of the Norwegian Cancer Society (NCS) publish articles about scientists they support regularly, written in a popular scientific language (in Norwegian). They have recently published a piece about the research on the use of cancer vaccines in order to fight Follicular lymphoma, performed by the research groups led by Arne Kolstad and Johanne Olweus at the Department of Oncology and the Institute for Cancer Research, Oslo University Hospital.
Kristin Bjordal, head of research at the Oslo Hospital Services division and professor II at the Institute of Clinical Medicine, UiO, has recently written for the the Oslo University Hospital research blog (in Norwegian). She discusses various aspects of participating in clinical studies, including risks and gains.
Maria EB Berstad and Anette Weyergang in Kristian Bergs Photochemical internalisation (PCI) research group are the first and last authors of a recent publication in Oncogene (journal impact factor 8.6) on design and evaluation of an EGFR targeting toxin for photochemical delivery.
The Department of Molecular Oncology has in collaboration with the Norwegian PSC Research Center at Oslo University Hospital, Rikshospitalet, recently published a paper in Hepatology (journal impact factor 11.19) where a high-performance epigenetic biomarker panel suitable for identifying patients with bile duct cancer was described. First author is post doc Kim Andresen from Guro E. Lind's Epigenetics group at the Department of Molecular Oncology at the Institute for Cancer Research (photo).
Seminar with the winners of the Olav Thon Foundation International Research Prize
Mar 2, 2015
Feb 26, 2015
Feb 25, 2015
Feb 24, 2015
Inst. for Cancer Research
Functional specialization of chordate CDK1 paralogs during oogenic meiosis
Cell Cycle, 0 (in press)
Investigation of established genetic risk variants for glioma in pre-diagnostic samples from a population based nested case control study
Cancer Epidemiol Biomarkers Prev (in press)
Journal Impact Factor > 5, first or last author from the Institute for Cancer Research
Photochemical Internalization of Tamoxifens Transported by a "Trojan-Horse" Nanoconjugate into Breast-Cancer Cell Lines
Angew Chem Int Ed Engl (in press)